Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (2274)
All Articles published online
|
Oct 28, 2007 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-α therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13(40): 5343-5350 [PMID: 17879404 DOI: 10.3748/wjg.v13.i40.5343] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i40/5343.htm |
| Number | Citing Articles |
| 1 |
Kensaku Sanefuji, Hiroto Kayashima, Tomohiro Iguchi, Keishi Sugimachi, Yo‐ichi Yamashita, Tomoharu Yoshizumi, Yuji Soejima, Takashi Nishizaki, Akinobu Taketomi, Yoshihiko Maehara. Characterization of hepatocellular carcinoma developed after achieving sustained virological response to interferon therapy for hepatitis C. Journal of Surgical Oncology 2009; 99(1): 32 doi: 10.1002/jso.21176
|
| 2 |
Alajos Pár. Prophylaxis and treatment of chronic viral hepatitis as the prevention of hepatocellular carcinoma. Orvosi Hetilap 2009; 150(1): 19 doi: 10.1556/oh.2009.28529
|
| 3 |
Satoshi Miuma, Junya Miyamoto, Naota Taura, Masanori Fukushima, Ryu Sasaki, Masafumi Haraguchi, Hidetaka Shibata, Shuntaro Sato, Hisamitsu Miyaaki, Kazuhiko Nakao. Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis. Internal Medicine 2020; 59(7): 901 doi: 10.2169/internalmedicine.3382-19
|
| 4 |
Qing Pang, Kai Qu, Jian-Bin Bi, Su-Shun Liu, Jing-Yao Zhang, Si-Dong Song, Ting Lin, Xin-Sen Xu, Yong Wan, Ming-Hui Tai, Hao-Chen Liu, Ya-Feng Dong, Chang Liu. Thrombocytopenia for prediction of hepatocellular carcinoma recurrence: Systematic review and meta-analysis. World Journal of Gastroenterology 2015; 21(25): 7895-7906 doi: 10.3748/wjg.v21.i25.7895
|
| 5 |
Taro Takami, Takahiro Yamasaki, Issei Saeki, Toshihiko Matsumoto, Yutaka Suehiro, Isao Sakaida. Supportive therapies for prevention of hepatocellular carcinoma recurrence and preservation of liver function. World Journal of Gastroenterology 2016; 22(32): 7252-7263 doi: 10.3748/wjg.v22.i32.7252
|
| 6 |
Zhaohui Zhang, Yi Zhang, Wei Wang, Yunpeng Hua, Linyun Liu, Shunli Shen, Baogang Peng. Thrombocytopenia and the outcomes of hepatectomy for hepatocellular carcinoma: a meta-analysis. Journal of Surgical Research 2017; 210: 99 doi: 10.1016/j.jss.2016.11.002
|
| 7 |
Soji Shimomura, Shuhei Nishiguchi. Anticarcinogenic impact of interferon therapy on the progression of hepatocellular carcinoma in patients with chronic viral infection. Hepatology Research 2012; 42(1): 22 doi: 10.1111/j.1872-034X.2011.00889.x
|
| 8 |
Reem Waziry, Behzad Hajarizadeh, Jason Grebely, Janaki Amin, Matthew Law, Mark Danta, Jacob George, Gregory J. Dore. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. Journal of Hepatology 2017; 67(6): 1204 doi: 10.1016/j.jhep.2017.07.025
|
| 9 |
Amit Singal, Jorge A. Marrero. Yamada' s Textbook of Gastroenterology. 2015; : 2146 doi: 10.1002/9781118512074.ch109
|
| 10 |
Hong-Bo Huan, Li-Li Wu, Wan-Yee Lau, Xu-Dong Wen, Liang Zhang, Da-Peng Yang, Xi-Shu Wang, Ping Bie, Feng Xia. Surrogate endpoint for overall survival in assessment of adjuvant therapies after curative treatment for hepatocellular carcinoma: a re-analysis of meta-analyses of individual patients’ data. Oncotarget 2017; 8(52): 90291 doi: 10.18632/oncotarget.18853
|
| 11 |
Walaa Abdelhamed, Mohamed El-Kassas. Hepatocellular carcinoma recurrence: Predictors and management. Liver Research 2023; 7(4): 321 doi: 10.1016/j.livres.2023.11.004
|
| 12 |
WEI ZHANG, TIAN-QIANG SONG, TI ZHANG, QIANG WU, DA-LU KONG, QIANG LI, HUI-CHUAN SUN. Adjuvant interferon for early or late recurrence of hepatocellular carcinoma and mortality from hepatocellular carcinoma following curative treatment: A meta-analysis with comparison of different types of hepatitis. Molecular and Clinical Oncology 2014; 2(6): 1125 doi: 10.3892/mco.2014.386
|
| 13 |
Kenji Ikeda, Masahiro Kobayashi, Yuya Seko, Norihiro Imai, Miharu Hirakawa, Yusuke Kawamura, Hitomi Sezaki, Tetsuya Hosaka, Norio Akuta, Satoshi Saitoh, Fumitaka Suzuki, Yoshiyuki Suzuki, Yasuji Arase, Hiromitsu Kumada. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus‐related liver cancer. Hepatology Research 2010; 40(12): 1168 doi: 10.1111/j.1872-034X.2010.00720.x
|
| 14 |
S. Petta, G. Cabibbo, M. Barbara, S. Attardo, L. Bucci, F. Farinati, E. G. Giannini, F. Tovoli, F. Ciccarese, G. L. Rapaccini, M. Di Marco, E. Caturelli, M. Zoli, F. Borzio, R. Sacco, R. Virdone, F. Marra, M. Felder, F. Morisco, L. Benvegnù, A. Gasbarrini, G. Svegliati‐Baroni, F. G. Foschi, A. Olivani, A. Masotto, G. Nardone, A. Colecchia, M. Persico, V. Boccaccio, A. Craxì, S. Bruno, F. Trevisani, C. Cammà. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Alimentary Pharmacology & Therapeutics 2017; 45(1): 160 doi: 10.1111/apt.13821
|
| 15 |
Gabriella Lengyel, János Fehér†. Combined interferon, ribavirin treatment and the occurrence of hepatocellular carcinoma. Orvosi Hetilap 2010; 151(29): 1177 doi: 10.1556/oh.2010.28925
|
| 16 |
Mohamed Elbadry, Abdelmajeed M. Moussa, Mohamed Eltabbakh, Amira Al Balakosy, Mohammad Abdalgaber, Nermeen Abdeen, Reem Y. El Sheemy, Shimaa Afify, Mohamed El-Kassas. The art of managing hepatitis C virus in special population groups: a paradigm shift. Egyptian Liver Journal 2022; 12(1) doi: 10.1186/s43066-022-00226-8
|
| 17 |
Tatehiro Kagawa, Emmet B. Keeffe. Long-Term Effects of Antiviral Therapy in Patients with Chronic Hepatitis C. Hepatitis Research and Treatment 2010; 2010: 1 doi: 10.1155/2010/562578
|
| 18 |
Masayuki Sakae, Shoji Kubo, Shigekazu Takemura, Chikaharu Sakata, Takahiro Uenishi, Shintaro Kodai, Hiroji Shinkawa, Yorihisa Urata, Kazunori Ohata, Kazuhisa Kaneda, Takayoshi Nishioka, Akinori Nozawa, Shigefumi Suehiro. Effect of interferon therapy on first and second recurrence after resection of hepatitis C virus‐related hepatocellular carcinoma. Hepatology Research 2012; 42(6): 564 doi: 10.1111/j.1872-034X.2011.00959.x
|
| 19 |
Koji Waki, Hiroshi Aikata, Yoshio Katamura, Tomokazu Kawaoka, Shintaro Takaki, Akira Hiramatsu, Shoichi Takahashi, Naoyuki Toyota, Katsuhide Ito, Kazuaki Chayama. Percutaneous radiofrequency ablation as first‐line treatment for small hepatocellular carcinoma: Results and prognostic factors on long‐term follow up. Journal of Gastroenterology and Hepatology 2010; 25(3): 597 doi: 10.1111/j.1440-1746.2009.06125.x
|
| 20 |
Sho Okimoto, Tsuyoshi Kobayashi, Shintaro Kuroda, Kohei Ishiyama, Kentaro Ide, Masahiro Ohira, Hiroyuki Tahara, Seiichi Shimizu, Hiroshi Iwako, Michinori Hamaoka, Naruhiko Honmyo, Megumi Yamaguchi, Hideki Ohdan. Prediction of recurrence following hepatectomy in patients with hepatitis C virus infection‐related hepatocellular carcinoma who achieved a sustained virological response. Hepatology Research 2017; 47(11): 1186 doi: 10.1111/hepr.12896
|
| 21 |
Ying-Chun Shen, Chiun Hsu, Li-Tzong Chen, Chia-Chi Cheng, Fu-Chang Hu, Ann-Lii Cheng. Adjuvant interferon therapy after curative therapy for hepatocellular carcinoma (HCC): A meta-regression approach. Journal of Hepatology 2010; 52(6): 889 doi: 10.1016/j.jhep.2009.12.041
|
| 22 |
Ying-Chieh Chen, Wei Teng, Yi-Chung Hsieh, Wei-Ting Chen, Wen-Juei Jeng, Chien-Hao Huang, Chen-Chun Lin, Yi-Cheng Chen, Shi-Ming Lin, Chun-Yen Lin, I-Shyan Sheen. Timely eradication of HCV viremia by PegIFN/RBV is crucial in prevention of post RFA recurrence in CHC-HCC patients. Journal of the Formosan Medical Association 2019; 118(8): 1239 doi: 10.1016/j.jfma.2018.11.014
|
| 23 |
Yan Du, Tong Su, Yibo Ding, Guangwen Cao. Effects of Antiviral Therapy on the Recurrence of Hepatocellular Carcinoma After Curative Resection or Liver Transplantation. Hepatitis Monthly 2012; 12(10) doi: 10.5812/hepatmon.6031
|
| 24 |
Giuseppe Cabibbo, Salvatore Petta, Marco Barbàra, Gabriele Missale, Roberto Virdone, Eugenio Caturelli, Fabio Piscaglia, Filomena Morisco, Antonio Colecchia, Fabio Farinati, Edoardo Giannini, Franco Trevisani, Antonio Craxì, Massimo Colombo, Calogero Cammà. A meta‐analysis of single HCV‐untreated arm of studies evaluating outcomes after curative treatments of HCV‐related hepatocellular carcinoma. Liver International 2017; 37(8): 1157 doi: 10.1111/liv.13357
|
| 25 |
Chia-Chi Wang, Jia-Horng Kao. How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma?. Expert Opinion on Pharmacotherapy 2016; 17(7): 911 doi: 10.1517/14656566.2016.1149165
|
| 26 |
Yoshisato Tanimoto, Hirotaka Tashiro, Hiroshi Aikata, Hironobu Amano, Akihiko Oshita, Tsuyoshi Kobayashi, Shintaro Kuroda, Hirofumi Tazawa, Shoichi Takahashi, Toshiyuki Itamoto, Kazuaki Chayama, Hideki Ohdan. Impact of Pegylated Interferon Therapy on Outcomes of Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma After Curative Hepatic Resection. Annals of Surgical Oncology 2012; 19(2): 418 doi: 10.1245/s10434-011-1866-1
|
| 27 |
Naoya Kanogawa, Sadahisa Ogasawara, Tetsuhiro Chiba, Tomoko Saito, Tenyu Motoyama, Eiichiro Suzuki, Yoshihiko Ooka, Akinobu Tawada, Tatsuo Kanda, Shigeru Mikami, Ryosaku Azemoto, Takashi Kaiho, Masami Shinozaki, Masayuki Ohtsuka, Masaru Miyazaki, Osamu Yokosuka. Sustained virologic response achieved after curative treatment of hepatitis C virus‐related hepatocellular carcinoma as an independent prognostic factor. Journal of Gastroenterology and Hepatology 2015; 30(7): 1197 doi: 10.1111/jgh.12925
|
| 28 |
Y. Miyake, A. Takaki, Y. Iwasaki, K. Yamamoto. Meta-analysis: interferon-alpha prevents the recurrence after curative treatment of hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis 2010; 17(4): 287 doi: 10.1111/j.1365-2893.2009.01181.x
|
| 29 |
A. K. Singal, D. H. Freeman Jr, B. S. Anand. Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Alimentary Pharmacology & Therapeutics 2010; 32(7): 851 doi: 10.1111/j.1365-2036.2010.04414.x
|
| 30 |
Sashidhar Manthravadi, Swathi Paleti, Prashant Pandya. Impact of sustained viral response postcurative therapy of hepatitis C‐related hepatocellular carcinoma: a systematic review and meta‐analysis. International Journal of Cancer 2017; 140(5): 1042 doi: 10.1002/ijc.30521
|
| 31 |
Wei Teng, Yen-Chun Liu, Wen-Juei Jeng, Chien-Wei Su. Tertiary Prevention of HCC in Chronic Hepatitis B or C Infected Patients. Cancers 2021; 13(7): 1729 doi: 10.3390/cancers13071729
|
| 32 |
Gisèle N'Kontchou, Amel Mahamoudi, Mounir Aout, Nathalie Ganne-Carrié, Véronique Grando, Emmanuelle Coderc, Eric Vicaut, Jean Claude Trinchet, Nicolas Sellier, Michel Beaugrand, Olivier Seror. Radiofrequency ablation of hepatocellular carcinoma: Long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology 2009; 50(5): 1475 doi: 10.1002/hep.23181
|
| 33 |
Shinji Takashimizu, Sei-ichiro Kojima, Junko Nagata, Yasuhiro Nishizaki, Tatehiro Kagawa, Koichi Shiraishi, Tetsuya Mine, Jun-ichi Kaneko, Norihiro Kokudo, Norihito Watanabe. Intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma developed after a 6-year sustained virological response to interferon therapy for chronic hepatitis C. Clinical Journal of Gastroenterology 2011; 4(3): 167 doi: 10.1007/s12328-011-0216-y
|
| 34 |
T.‐S. Huang, Y.‐C. Shyu, H.‐Y. Chen, S.‐S. Yuan, J.‐N. Shih, P.‐J. Chen. A systematic review and meta‐analysis of adjuvant interferon therapy after curative treatment for patients with viral hepatitis‐related hepatocellular carcinoma. Journal of Viral Hepatitis 2013; 20(10): 729 doi: 10.1111/jvh.12096
|
| 35 |
Soji Shimomura, Naoto Ikeda, Masaki Saito, Akio Ishii, Tomoyuki Takashima, Yoshiyuki Sakai, Shohei Yoshikawa, Nobuhiro Aizawa, Hironori Tanaka, Yoshinori Iwata, Hirayuki Enomoto, Hiroyasu Imanishi, Teruhisa Yamamoto, Hisato Jomura, Hideji Nakamura, Hiroko Iijima, Shuhei Nishiguchi. Long-term interferon therapy after radiofrequency ablation is effective in treating patients with HCV-associated hepatocellular carcinoma. Hepatology International 2011; 5(1): 559 doi: 10.1007/s12072-010-9214-2
|
| 36 |
T. Kawaoka, H. Aikata, S. Takaki, A. Hiramatsu, K. Waki, N. Hiraga, D. Miki, M. Tsuge, M. Imamura, Y. Kawakami, S. Takahashi, H. Ochi, H. Tashiro, H. Ohdan, K. Chayama. IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma. Journal of Viral Hepatitis 2011; 18(10): e550 doi: 10.1111/j.1365-2893.2011.01468.x
|